Effect of PEA-OXA on neuropathic pain and functional recovery after sciatic nerve crush
Tóm tắt
Animal models of sciatic nerve injury are commonly used to study neuropathic pain as well as axon regeneration. Inflammation/immune response at the site of nerve lesion is known to be an essential trigger of the pathological changes that have a critical impact on nerve repair and regeneration; moreover, the damage to peripheral nerve can cause a loss of sensory function and produces a persistent neuropathic pain. N-Acylethanolamines (NAEs) involve a family of lipid molecules existent in animal and plant, of which is N-palmitoylethanolamide (PEA) that arouses great attention owing to its anti-inflammatory, analgesic, and neuroprotective activities. The modulation of specific amidases for NAEs (and in particular NAE-hydrolyzing acid amidase NAAA, which is more selective for PEA) could be a condition to preserve its levels. Here, we investigated, in a mice model of sciatic nerve crush, the effect of 2-pentadecyl-2-oxazoline (PEA-OXA) the oxazoline of PEA that reportedly modulates activity of NAAA. In this experimental model, the mice, following the sciatic nerve crush, were treated daily with PEA-OXA at a dose of 10 mg\kg for 14 days. Therefore, we evaluated the effects of PEA-OXA on the degree of injury, on the inhibition of neuropathic pain, and on the inflammatory process, as in the improvement of reparative processes and therefore in the restoration of locomotor function. Our results showed that PEA-OXA (10 mg/kg) treatment, daily, for 14 days after sciatic nerve crush, have an anti-inflammatory and neuroprotective effect and moreover have an analgesic protective effect on hypersensitivity, and improve the functional recovery after nerve crush. Therefore, treatment with PEA-OXA as a whole has shown a protective effect, which makes it a powerful candidate for the treatment of peripheral nerve injury and neuropathic pain.
Tài liệu tham khảo
Koeppen AH. Wallerian degeneration: history and clinical significance. J Neurol Sci. 2004;220(1–2):115–7.
Gureje O, Von Korff M, Ge S, Gater R. Persistent pain and well-being: a world health organization study in primary care. JAMA. 1998;280(2):147–51.
CD B, Gilroy DW, Serhan CN, Stockinger B, Tak PP. The resolution of inflammation. Nat Rev Immunol. 2013;13(1):59–66.
Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.
Di Marzo V, Skaper SD. Palmitoylethanolamide: biochemistry, pharmacology and therapeutic use of a pleiotropic anti-inflammatory lipid mediator. CNS Neurol Disord Drug Targets. 2013;12(1):4–6.
Skaper SD, Facci L, Barbierato M, Zusso M, Bruschetta G, Impellizzeri D, et al. N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. Mol Neurobiol. 2015;52(2):1034–42.
Guida F, Luongo L, Marmo F, Romano R, Iannotta M, Napolitano F, et al. Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice. Mol Brain. 2015;8:47.
Di Cesare Mannelli L, Pacini A, Corti F, Boccella S, Luongo L, Esposito E, et al. Antineuropathic profile of n-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity. PLoS One. 2015;10(6):e0128080.
Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015;8:729–34.
Bertolino B, Crupi R, Impellizzeri D, Bruschetta G, Cordaro M, Siracusa R, et al. Beneficial effects of co-ultramicronized palmitoylethanolamide/luteolin in a mouse model of autism and in a case report of autism. CNS Neurosci Ther. 2017;23(1):87–98.
Tsuboi K, Takezaki N, Ueda N. The N-acylethanolamine-hydrolyzing acid amidase (naaa). Chem Biodivers. 2007;4(8):1914–25.
Starowicz K, Makuch W, Korostynski M, Malek N, Slezak M, Zychowska M, et al. Full inhibition of spinal faah leads to trpv1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. PLoS One. 2013;8(4):e60040.
Impellizzeri D, Cordaro M, Bruschetta G, Crupi R, Pascali J, Alfonsi D, et al. 2-Pentadecyl-2-oxazoline: identification in coffee, synthesis and activity in a rat model of carrageenan-induced hindpaw inflammation. Pharmacol Res. 2016;108:23–30.
Morrison BM, Tsingalia A, Vidensky S, Lee Y, Jin L, Farah MH, et al. Deficiency in monocarboxylate transporter 1 (mct1) in mice delays regeneration of peripheral nerves following sciatic nerve crush. Exp Neurol. 2015;263:325–38.
Gugliandolo E, Fusco R, D'amico R, Militi A, Oteri G, Wallace JL, Cuzzocrea S. Anti-inflammatory effect of ATB-352, a H2S− releasing ketoprofen derivative, on lipopolysaccharide-induced periodontitis in rats. Pharmacol Res. 2018;132:220–31.
Smith CJ, Allard DE, Wang Y, Howard JF Jr, Montgomery SA, Su MA. Il-10 paradoxically promotes autoimmune neuropathy through s1pr1-dependent cd4(+) t cell migration. J Immunol. 2018;200(5):1580–92.
Impellizzeri D, Campolo M, Bruschetta G, Crupi R, Cordaro M, Paterniti I, et al. Traumatic brain injury leads to development of parkinson's disease related pathology in mice. Front Neurosci. 2016;10:458.
Zhou D, Masliah E, Spector SA. Autophagy is increased in postmortem brains of persons with hiv-1-associated encephalitis. J Infect Dis. 2011;203(11):1647–57.
Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32(1):77–88.
Choi S, Na HS, Kim J, Lee J, Lee S, Kim D, et al. Attenuated pain responses in mice lacking ca(v)3.2 t-type channels. Genes Brain Behav. 2007;6(5):425–31.
Taylor MD, Holdeman AS, Weltmer SG, Ryals JM, Wright DE. Modulation of muscle spindle innervation by neurotrophin-3 following nerve injury. Exp Neurol. 2005;191(1):211–22.
Taylor MD, Vancura R, Williams JM, Riekhof JT, Taylor BK, Wright DE. Overexpression of neurotrophin-3 in skeletal muscle alters normal and injury-induced limb control. Somatosens Mot Res. 2001;18(4):286–94.
JW Z, YF L, ZT W, WQ J, RX X. Toll-like receptor 4 deficiency impairs motor coordination. Front Neurosci. 2016;10:33.
Kato N, Matsumoto M, Kogawa M, Atkins GJ, Findlay DM, Fujikawa T, et al. Critical role of p38 mapk for regeneration of the sciatic nerve following crush injury in vivo. J Neuroinflammation. 2013;10:1.
Petrosino S, Campolo M, Impellizzeri D, Paterniti I, Allara M, Gugliandolo E, et al. 2-Pentadecyl-2-oxazoline, the oxazoline of pea, modulates carrageenan-induced acute inflammation. Front Pharmacol. 2017;8:308.
Moalem G, DJ T. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev. 2006;51(2):240–64.
Karsidag S, Ozcan A, Sahin S, Karsidag S, Kabukcuoglu F, Ugurlu K, et al. Electrophysiologic and histopathologic evaluation of peripheral nerve regeneration at different nerve segments and with different repair techniques. Acta Orthop Traumatol Turc. 2008;42(4):278–83.
Tos P, Ronchi G, Papalia I, Sallen V, Legagneux J, Geuna S, et al. Chapter 4: Methods and protocols in peripheral nerve regeneration experimental research: part i-experimental models. Int Rev Neurobiol. 2009;87:47–79.
Esposito E, Cuzzocrea S. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma. Mini Rev Med Chem. 2013;13(2):237–55.
Sasso O, Moreno-Sanz G, Martucci C, Realini N, Dionisi M, Mengatto L, et al. Antinociceptive effects of the n-acylethanolamine acid amidase inhibitor arn077 in rodent pain models. Pain. 2013;154(3):350–60.
Moskowitz PF, Oblinger MM. Sensory neurons selectively upregulate synthesis and transport of the beta iii-tubulin protein during axonal regeneration. J Neurosci. 1995;15(2):1545–55.
Moskowitz PF, Smith R, Pickett J, Frankfurter A, Oblinger MM. Expression of the class iii beta-tubulin gene during axonal regeneration of rat dorsal root ganglion neurons. J Neurosci Res. 1993;34(1):129–34.
Zuo Y, Perkins NM, Tracey DJ, Geczy CL. Inflammation and hyperalgesia induced by nerve injury in the rat: a key role of mast cells. Pain. 2003;105(3):467–79.
Zochodne DW, Nguyen C, Sharkey KA. Accumulation and degranulation of mast cells in experimental neuromas. Neurosci Lett. 1994;182(1):3–6.
Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev. 1997;77(4):1033–79.
Raffa RB. Antihistamines as analgesics. J Clin Pharm Ther. 2001;26(2):81–5.
Kudo K, Takahashi T, Suzuki S. The changes of c-fos expression by motor cortex stimulation in the deafferentation pain model. Neurol Med Chir (Tokyo). 2014;54(7):537–44.
Bester H, Beggs S, Woolf CJ. Changes in tactile stimuli-induced behavior and c-fos expression in the superficial dorsal horn and in parabrachial nuclei after sciatic nerve crush. J Comp Neurol. 2000;428(1):45–61.
Yang L, Li L, Chen L, Li Y, Chen H, Li Y, et al. Potential analgesic effects of a novel N-acylethanolamine acid amidase inhibitor f96 through ppar-alpha. Sci Rep. 2015;5:13565.
Ellis A, DL B. Neuroinflammation and the generation of neuropathic pain. Br J Anaesth. 2013;111(1):26–37.
Yin Q, Fan Q, Zhao Y, Cheng MY, Liu H, Li J, et al. Spinal nf-kappab and chemokine ligand 5 expression during spinal glial cell activation in a neuropathic pain model. PLoS One. 2015;10(1):e0115120.
Kernie SG, Erwin TM, Parada LF. Brain remodeling due to neuronal and astrocytic proliferation after controlled cortical injury in mice. J Neurosci Res. 2001;66(3):317–26.
Zhao M, Liang F, Xu H, Yan W, Zhang J. Methylene blue exerts a neuroprotective effect against traumatic brain injury by promoting autophagy and inhibiting microglial activation. Mol Med Rep. 2016;13(1):13–20.
Tsuda M, Masuda T, Tozaki-Saitoh H, Inoue K. Microglial regulation of neuropathic pain. J Pharmacol Sci. 2013;121(2):89–94.
Nakagawa T, Kaneko S. Spinal astrocytes as therapeutic targets for pathological pain. J Pharmacol Sci. 2010;114(4):347–53.
Zhang T, Li Z, Dong J, Nan F, Li T, Yu Q. Edaravone promotes functional recovery after mechanical peripheral nerve injury. Neural Regen Res. 2014;9(18):1709–15.
Stenberg L, Kanje M, Dolezal K, LB D. Expression of activating transcription factor 3 (atf 3) and caspase 3 in schwann cells and axonal outgrowth after sciatic nerve repair in diabetic bb rats. Neurosci Lett. 2012;515(1):34–8.
Renno WM, Al-Maghrebi M, Rao MS, Khraishah H. (-)-Epigallocatechin-3-gallate modulates spinal cord neuronal degeneration by enhancing growth-associated protein 43, b-cell lymphoma 2, and decreasing b-cell lymphoma 2-associated x protein expression after sciatic nerve crush injury. J Neurotrauma. 2015;32(3):170–84.
Gumus B, Kuyucu E, Erbas O, Kazimoglu C, Oltulu F, OA B. Effect of oxytocin administration on nerve recovery in the rat sciatic nerve damage model. J Orthop Surg Res. 2015;10:161.
Khan N, MT S. Neurotrophins and neuropathic pain: role in pathobiology. Molecules. 2015;20(6):10657–88.
Iulita MF, Caraci F, AC C. A link between nerve growth factor metabolic deregulation and amyloid-beta-driven inflammation in Down syndrome. CNS Neurol Disord Drug Targets. 2016;15(4):434–47.
Ramesh G, Maclean AG, Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediat Inflamm. 2013;2013:480739.
George LT, Myckatyn TM, Jensen JN, Hunter DA, Mackinnon SE. Functional recovery and histomorphometric assessment following tibial nerve injury in the mouse. J Reconstr Microsurg. 2003;19(1):41–8.